Αποτελέσματα Αναζήτησης
On admission, patients in both groups were treated according to European recommendations with restricted fluid expansion and early transfusion of blood products with a PRBC:FFP ratio between 1:1 and 2:1.
30 Οκτ 2024 · Nevertheless, andexanet alfa was associated with an increased incidence of thrombotic events (10.3% vs. 5.6%; adjusted difference, 4.6; 95% CI, 0.1 to 9.2; P = 0.048), including ischemic stroke (6.5% vs. 1.5%). 80 In cases of mild traumatic brain injury, the use of 4F-PCC for factor Xa inhibitor–associated intracerebral hemorrhage did not ...
17 Ιουλ 2020 · In patients taking direct oral anticoagulants undergoing emergency surgery, four-factor prothrombin complex concentrate with a dose of 2000 IU (approximately 25 IU.kg -1) is a rescue therapy, when a specific antidote is not available.
2 Αυγ 2020 · Prothrombin complex concentrate (PCC) is increasingly being used as a treatment for major bleeding in patients who are not taking anticoagulants. The aim of this systematic review and meta‐analysis is to evaluate the effectiveness of PCC administration for the treatment of bleeding in patients not taking anticoagulants.
2 Νοε 2023 · Trauma-induced coagulopathy (TIC) is common in trauma patients with major hemorrhage. Prothrombin complex concentrate (PCC) is used as a potential treatment for the correction of TIC, but the efficacy, timing, and evidence to support its use in injured patients with hemorrhage are unclear.
Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial.
3 Δεκ 2018 · Currently, the treatment options for the management of direct oral anticoagulant (DOAC)-associated bleeding are limited. Prothrombin complex concentrates (PCCs) have been proposed as a potential therapeutic option, and evidence regarding their use is increasing.
